Related Experiment Videos
Perceptions of Saskatchewan community pharmacists regarding a prior-authorization program.
Jason Perepelkin1, Roy Thomas Dobson
1College of Pharmacy & Nutirtion, University of Saskatchewan, Canada. jason.perepelkin@usask.ca
Journal of Managed Care Pharmacy : JMCP
|September 19, 2007
Summary
Pharmacists in Saskatchewan find the prior authorization (PA) program beneficial for patients, but administrative burdens exist. Key factors for successful PA requests include obtaining patient diagnosis and physician contact, not pharmacist time.
Area of Science:
- Pharmacy Practice
- Health Services Research
- Medication Access
Background:
- Since 1999, Saskatchewan pharmacists can initiate exception drug status (EDS) or prior authorization (PA) requests.
- Previously, only prescribers could initiate these requests.
- Pharmacists require a physician-provided patient diagnosis for EDS requests.
Purpose of the Study:
- To evaluate pharmacists' perceptions of the Saskatchewan drug Plan's PA program benefits.
- To identify factors influencing pharmacist-initiated EDS requests.
Main Methods:
- A census survey of community pharmacy managers in Saskatchewan was conducted in 2004.
- A self-administered postal questionnaire was used.
- Responses were collected on behalf of all pharmacists within each pharmacy.
Main Results:
- An 82.6% response rate was achieved.
- Most pharmacists agreed PA benefits patients (87.3%) and the drug plan (82.5%), but fewer saw benefits for themselves (33.4%).
- Key factors were information access (87.6%), physician contact (87.3%), and patient affordability (85.1%); pharmacist time was not significant.
Conclusions:
- Community pharmacists in Saskatchewan recognize the patient benefits of the EDS/PA process.
- Pharmacists face administrative challenges, particularly in obtaining essential patient diagnostic information.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...